Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke (NCT07095790) | Clinical Trial Compass
RecruitingPhase 4
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
China580 participantsStarted 2025-08-30
Plain-language summary
This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.
Who can participate
Age range18 Years ā 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age: 18-80 years old.
ā. Acute mild non-cardioembolic stroke.
ā. NIHSS score ā¤5.
ā. Time from onset to randomization of ā¤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ā¤48 hours.
ā. The investigational drug can be administered within 48 hours of symptom onset.
ā. Signed informed consent by the patient or legally authorized representative.
Exclusion criteria
ā. Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
ā. Intracranial hemorrhage confirmed by imaging.